Phase I/II study of CT-2106 in combination with infusional 5-fluorouracil/folinic Acid (5-FU/FA) (De Gramont Schedule) as second line in patients with metastatic colorectal cancer failing an oxaliplatin plus 5-FU/FA regimen.

Trial Profile

Phase I/II study of CT-2106 in combination with infusional 5-fluorouracil/folinic Acid (5-FU/FA) (De Gramont Schedule) as second line in patients with metastatic colorectal cancer failing an oxaliplatin plus 5-FU/FA regimen.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 Jul 2014

At a glance

  • Drugs CT 2106 (Primary) ; Fluorouracil; Folinic acid
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors CTI BioPharma
  • Most Recent Events

    • 21 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Aug 2006 The expected completion date for this trial is now 1 Apr 2007.
    • 13 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top